We serve Chemical Name:5-Fluoro-2,1,3-benzothiadiazole CAS:17821-75-9 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:5-Fluoro-2,1,3-benzothiadiazole
CAS.NO:17821-75-9
Synonyms:5-fluoro-2,1,3-benzothiadiazol;MFCD00173946;2,1,3-Benzothiadiazole, 5-fluoro-;5-Fluoro-2,1,3-benzothiadiazole;5-Fluorobenzo-[2,1,3]-thiadiazole;5-fluorobenzo[c]1,2,5-thiadiazole;5-fluoro-[2,1,3]-benzothiadiazole;5-Fluor-2,1,3-benzothiadiazol
Molecular Formula:C6H3FN2S
Molecular Weight:154.165
HS Code:2934999090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:211.4±13.0 °C at 760 mmHg
Density:1.5±0.1 g/cm3
Index of Refraction:1.668
PSA:54.02000
Exact Mass:154.000092
LogP:2.03
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 5-fluoro-2,1,3-benzothiadiazol chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,5-Fluor-2,1,3-benzothiadiazol physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,5-Fluoro-2,1,3-benzothiadiazole Use and application,2,1,3-Benzothiadiazole, 5-fluoro- technical grade,usp/ep/jp grade.
Related News: I believe they came to the right decision on behalf of the American public, Sandrock said in an interview. 5-Fluoro-2,1,3-benzothiadiazole manufacturer Retrogenix��s extensive library of human proteins make it uniquely placed for assessing candidate antibodies for target binding. 5-Fluoro-2,1,3-benzothiadiazole supplier Retrogenix��s extensive library of human proteins make it uniquely placed for assessing candidate antibodies for target binding. 5-Fluoro-2,1,3-benzothiadiazole vendor Retrogenix��s extensive library of human proteins make it uniquely placed for assessing candidate antibodies for target binding. 5-Fluoro-2,1,3-benzothiadiazole factory The results of analysis perfectly align with the tau hypothesis — simply put, if the patient is tau biomarker positive, then tau pathology is responsible for his/her cognitive decline, and halting tau pathology should slow or halt progression,” Novak said. “If the patient is negative for markers of tau pathology, then this patient’s impairment is mainly due to other pathologies, and treating tau pathology in this patient won’t be meaningful.
